Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer-Reference-Cited by-同舟云学术

Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer

Published:2019-11-26 Issue: Volume: Page:
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Pereira Marina Alessandra¹^ORCID,Ramos Marcus Fernando Kodama Pertille¹^ORCID,Dias Andre Roncon¹^ORCID,Cardili Leonardo¹^ORCID,Ribeiro Renan Ribeiro e¹^ORCID,Charruf Amir Zeide¹,Castria Tiago Biachi¹^ORCID,Zilberstein Bruno¹^ORCID,Ceconello Ivan¹,Avancini Ferreira Alves Venancio¹,Ribeiro Ulysses¹^ORCID,Mello Evandro Sobroza¹

Affiliation:

1. Instituto do Cancer, Hospital das Clinicas HCFMUSP, Faculdade de MedicinaUniversidade de Sao PauloSao Paulo Brazil

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.25785

Reference31 articles.

1. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

2. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

3. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)